"Truncal fat was associated with less JSN progression in female  patients. Smoking predicted erosion progression, and erosions may precede JSN.  BMI and fat distribution may influence cartilage damage in early RA and might  be related to hormonal factors."wrote the team.
    The findings have been put forth in Arthritis Research & Therapy.
    Radiographic damage in rheumatoid arthritis  (RA) includes erosions and joint space narrowing (JSN). Different mechanisms  may underlie their development. The presence of autoantibodies such as  rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs),  higher disease activity measures, and levels of systemic inflammation are  considered other established risk factors for worse radiological outcomes.  RA-related joint damage includes erosions and cartilage destruction, with the  latter causing joint space narrowing (JSN). Despite that separate scores of  these are included in the commonly used radiographic scoring methods , most  previous studies have evaluated only combined total scores of the radiographic  damage.
     
    With  this background,The objective of this study  was to evaluate predictors of these entities separately.
    An  inception cohort of 233 consecutive patients with early RA was investigated.  The catchment area was the city of Malmö, Sweden (population 259,579 in 2000).  Patients were recruited from the rheumatology outpatient clinic of Skåne  University Hospital Malmö, the only hospital serving the city, or from the four  rheumatologists in private practice in the area, between 1995 and 2005.
    The patients were diagnosed with RA by a  specialist in rheumatology, fulfilled the 1987 American College of Rheumatology  (ACR) classification criteria for RA  and had duration of symptoms ≤ 12 months  at the time of inclusion (baseline). There were no additional exclusion  criteria.
    Data  analysis revealed the following facts.
    - Two  hundred and thirty-three patients were included. Radiographs at baseline and  5 years were available for 162 patients. 
 - The  median (interquartile) progression of erosion and JSN scores were 4 (0–8) and 8  (1–16), respectively. 
 - Rheumatoid  factor (RF) was a robust significant predictor of both erosion and JSN score  progression. 
 - In  adjusted analyses, anti-CCP antibodies predicted erosions while the erythrocyte  sedimentation rate was predictive of both outcomes. Smoking and high baseline  disease activity (DAS28 > 5.1) predicted progression of erosions. 
 - Baseline  erosion score was associated with progression of both erosion and JSN  progression, while baseline JSN score was predictive only of the progression of  JSN. 
 - Overweight/obesity  (BMI ≥ 25 kg/m2) was a significant negative predictor of JSN  score progression (β = − 0.14, p = 0.018, adjusted for RF, age, baseline JSN  score) also when additionally adjusting for ever smoking (p = 0.041). 
 - Among  female patients, this effect was observed in those of estimated post-menopausal  age (> 51 years), but not in younger women. 
 - The  truncal to peripheral fat ratio was associated with less JSN score progression  in women, but not in men.
 
                                "Truncal fat was associated with less JSN  progression in female patients. Smoking predicted erosion progression, and  erosions may precede JSN. BMI and fat distribution may influence cartilage  damage in early RA and might be related to hormonal factors."the team  concluded.
    For the full article follow the link:  https://doi.org/10.1186/s13075-020-02413-7
    Primary source: Arthritis Research & Therapy
 
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.